Briefly, the test determines if the PTEN gene is functioning properly, as it is a tumor suppressor gene that is linked with cell regulation. If patients have a low level of the protein, studies have shown a progression of the cancer, while if the levels remain higher, the less chances of...
Posted to
The Medical Quack .... by Barbara Duck
on 12-22-2008
Filed under: Medically Related, Insurance, Pharma/FDA News, personalized medicine, Genomics, healthcare, Cancer, tumors, Chemotherapy, markers, PTEN gene, Myriad, diagnositic tests
Great interview from the Wall Street Journal, I guess when it comes time to go over the costs a patient gets to select to either find a method of payment if they can, or the other choice (no treatment) and we all know what the horrible results can be from there. The physicians are there to treat...